We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Aranesp Falters in Another Study of Off-Label Indications
Aranesp Falters in Another Study of Off-Label Indications
February 19, 2007
Amgen is facing more bad news regarding possible off-label uses of its drug Aranesp after independent study results pointed to adverse outcomes for a certain class of cancer patients prescribed the drug.